Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Estradiol; Fulvestrant

Criteria

Inclusion Criteria:

• Histologically confirmed, recurrent or metastatic endometrial carcinoma

• Postmenopausal

• Hormonreceptor positive

Exclusion Criteria:

• Pre-treatment with Fulvestrant

• Previous endocrine therapy of the endometrial carcinoma

• Previous malignancy less than 3 years ago other than in situ carcinoma of the cervix, basal cell carcinoma or squamous carcinoma of the skin